



Oncology bulletin

April 2025

The aim of this current awareness bulletin is to provide a digest of recent guidelines, reports, research and best practice on Oncology

If you would like to request any of the articles included in this bulletin, or be put onto the distribution list, please contact: ulth.library.grantham@nhs.net

For more information on Library and Knowledge Services please go to:
www.nhslincslibrary.uk

Cancer Treatments

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralization

Elaine Tomlins et al

British Journal of Nursing Vol 34 no 10 sup B S4-S15

Diagnosis

Thousands in the UK miss cancer screenings due to NHS error

More than 5000 people in the UK eligible for cancer screening did not receive a screening invitation from the National Health Service (NHS) due to administration errors dating back to 2008.

Priya Venkatesan

Lancet Oncology 26 (4) e189

Professional

Compassion training for healthcare professionals in oncology: A mixed-methods pilot study

Care and treatment within oncology is characterized by significant emotional demands from healthcare professionals resulting in burnout and distress. We examined the effect of compassion training on healthcare professionals using a mixed-methods explanatory sequential design

Henriette Witte et al

European Journal of Oncology Nursing 75 102808



Specific Cancers

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

Berend J van der Wilk et al

Lancet Oncology 26 (4) 425–36

Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study

Ziming Li et al

Lancet Oncology 26 (4) 437–46

Simple hysterectomy in early-stage cervical cancer: is it the way forward?

The recently published SHAPE trial demonstrated the non-inferiority of simple hysterectomy compared with its radical counterpart in the management of early-stage, low-risk cervical cancers. Additionally, the study found lower rates of urinary complications and improved sexual health outcomes with simple hysterectomy.

Pradip Kumar Saha et al

Gynecology and Obstetrics Clinical Medicine 5 (2) 300082 (open access)

Supercharged NK cells, unlike primary activated NK cells, effectively target ovarian cancer cells irrespective of MHC-class I expression

Article sets out to demonstrate the significance of supercharged natural killer (sNK) cells to target aggressive gynecological tumours

Sara Huerta-Yeppez et al

BMJ Oncology 4 e000618. (open access)

Induction chemotherapy for nasopharyngeal carcinoma

A new treatment option for locally advanced disease

Man Xu et al

BMJ 389 (8461) r652

Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial

To compare the effects of four cycles of docetaxel with cisplatin as a neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with concurrent chemoradiotherapy alone by assessing reductions in distant metastasis and improvements in survival in patients with stage N2-3 nasopharyngeal carcinoma



Wei-Hao Xie et al
BMJ 389 (8461) e081557 (open access)